Gleevec receives US approval as first treatment to reduce risk of cancer returning in patients with gastrointestinal stromal tumors - Video
MultiVu
Jan. 13, 2009. 04:52 PM EST
GIST, a life-threatening cancer, recurs in as many as one of two patients; recurrent tumors are o... More »
GIST, a life-threatening cancer, recurs in as many as one of two patients; recurrent tumors are often more aggressive than primary tumors « Less
Gleevec, FDA, approval, GIST, gastrointestinal, stromal, tumor, reduce, risk, relapse, patients, cancer, b25tYGtg, 35423, MultiVu, Cancer, Entertainment, Health, video
- RELATED CLIPS
-
Treatment plans to keep cancer from returning
WFTS ABC 28 Tampa, FL
Apr. 13, 2012. 05:46 PM EST
-
Bringing the heat to fight cancer
WPTV NBC5 West Palm Beach
Aug. 05, 2011. 05:20 AM EST
-
How do cancer patients pay for treatment?
WMAR ABC 2 Baltimore, MD
Jun. 03, 2011. 09:07 AM EST
-
Cancer Treatment Center of America
KTNV Las Vegas, NV
Jun. 02, 2011. 12:13 PM EST
-
SU2C Manage Your Treatment PSA - Video
MultiVu
Sep. 16, 2009. 01:52 PM EST
-
SU2C Manage Your Treatment PSA - Video
MultiVu
Sep. 16, 2009. 01:52 PM EST
-
SU2C Manage Your Treatment PSA - Video
MultiVu
Sep. 16, 2009. 01:52 PM EST
-
Reducing Risk of Infection for ICU Patients 1/2/09
WSYR ABC 9 Syracuse
Jan. 02, 2009. 06:43 PM EST
-
Reducing Risk of Infection for ICU Patients 12/31/08
WSYR ABC 9 Syracuse
Jan. 01, 2009. 10:18 AM EST
-
Cephalon, Inc., (Nasdaq: CEPH) Receives FDA Approval for TREANDA, T...
MultiVu
Nov. 03, 2008. 09:47 AM EST


